Patients with moderate to severe chronic spontaneous urticaria that were antihistamine-resistant to omalizumab experienced ...

already a $12 billion blockbuster in other indications – as well as Sanofi’s rival oral BTK inhibitor rilzabrutinib, which showed promise in a mid-stage trial and is heading for phase 3 trials ...

Another of Principia’s BTK inhibitors, rilzabrutinib, is being tested in phase 3 for patients with moderate to severe pemphigus, a rare and debilitating autoimmune disease that causes blistering ...

a Durable platelet response was defined as a platelet count of > 50 x 10 9 platelets/L for 6 of the last 8 weeks of the 24-week study period, with no rescue medication administered during the ...

Aims: To determine the maximum tolerated dose (MTD), safety and anti-tumor activity of afatinib combined with docetaxel in advanced cancer. Patients & methods: The MTD was determined from dose ...

When comparing the BLI/INO group to the chemotherapy group, the 2-year OS was 63% vs 31.2%, respectively, and the 2-year DFS was 49.6% vs 22.9%, respectively. Blinatumomab (BLI) and inotuzumab ...